Section 70
Chapter 69,888

Good Outcomes in Babies with in Utero Bedaquiline Exposure

Marais, B.J.

Clinical Infectious Diseases An Official Publication of the Infectious Diseases Society of America 72(7): 1169-1170


ISSN/ISBN: 1537-6591
PMID: 32141498
DOI: 10.1093/cid/ciaa174
Accession: 069887640

Download citation:  

The lymph node metastasis of colorectal cancer (LMN-CRC) seriously threatens the prognosis of patients. Chemotherapy, as the most common treatment, results in severe bone marrow suppression. 20(S)-ginsenoside Rh2 (SGRh2), a major effective constituent of ginseng, has demonstrated therapeutic effects on a variety of diseases, including some tumours. SGRh2 treatment had no effect on other organs. Therefore, ginsenosides are considered a safe and effective antineoplastic drug. However, the effects of SGRh2 on LMN-Crc remain unknown. The present study investigated the potential effect of SGRh2 on LMN-Crc in vitro and in vivo. SW480 and Co Lo205 cell lines were treated with SGRh2. SGRh2 dose-dependently decreased Crc cell proliferation by CCK-8, colony formation and Edu assays. The Transwell and scratch assays revealed that SGRh2 inhibits the migratory and invasive abilities of Crc cells in a dose-dependent manner. Furthermore, the results of Western blotting revealed that SGRh2 decreased the expression of matrix metalloproteinase (MMP)-2 and MMP9. In terms of the underlying mechanisms, SGRh2 regulates Crc metastasis by affecting epithelial-mesenchymal transition (EMT), which significantly up-regulated epithelial biomarkers (E-cadherin) and down-regulated mesenchymal biomarkers (N-cadherin and vimentin) and Emt transcriptional factors (Smad-3, Snail-1, and Twist-1). In vivo, SGRh2 significantly inhibited LMN-Crc without affecting other normal organs. Immunohistochemical results showed that SGRh2 treats LMN-Crc by regulating EMT. These results demonstrate that SGRh2 has therapeutic potential for LMN-CRC.

PDF emailed within 0-6 h: $19.90